240 related articles for article (PubMed ID: 24404140)
21. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
[TBL] [Abstract][Full Text] [Related]
22. Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of four protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection.
de Paula Oliveira Santos B; Trentini MM; Machado RB; Rúbia Nunes Celes M; Kipnis A; Petrovsky N; Junqueira-Kipnis AP
Hum Vaccin Immunother; 2017 Dec; 13(12):2967-2976. PubMed ID: 28937879
[TBL] [Abstract][Full Text] [Related]
23. Lyophilization Process Engineering and Thermostability of ID93 + GLA-SE, a Single-Vial Adjuvanted Subunit Tuberculosis Vaccine Candidate for Use in Clinical Studies.
Dutill TS; Archer MC; McCollum J; Press C; McNeill L; Hawkins L; Phan T; Laursen E; Cabullos R; Bouchard L; Castro RJ; Lin MW; Roco J; Blois C; Adeagbo B; Guderian JA; Gerhardt A; Beckmann AM; Trappler EH; Kramer RM; Fox CB
Front Drug Deliv; 2022; 2():. PubMed ID: 37771324
[TBL] [Abstract][Full Text] [Related]
24. CpG7909 adjuvant enhanced immunogenicity efficacy in mice immunized with ESAT6-Ag85A fusion protein, but does not confer significant protection against Mycobacterium tuberculosis infection.
Hu S; Chen H; Ma J; Chen Q; Deng H; Gong F; Huang H; Shi C
J Appl Microbiol; 2013 Nov; 115(5):1203-11. PubMed ID: 23902541
[TBL] [Abstract][Full Text] [Related]
25. A multistage-polyepitope vaccine protects against Mycobacterium tuberculosis infection in HLA-DR3 transgenic mice.
Geluk A; van den Eeden SJ; van Meijgaarden KE; Dijkman K; Franken KL; Ottenhoff TH
Vaccine; 2012 Dec; 30(52):7513-21. PubMed ID: 23103299
[TBL] [Abstract][Full Text] [Related]
26. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
[TBL] [Abstract][Full Text] [Related]
27. Fused Mycobacterium tuberculosis multi-stage immunogens with an Fc-delivery system as a promising approach for the development of a tuberculosis vaccine.
Mosavat A; Soleimanpour S; Farsiani H; Sadeghian H; Ghazvini K; Sankian M; Jamehdar SA; Rezaee SA
Infect Genet Evol; 2016 Apr; 39():163-172. PubMed ID: 26835592
[TBL] [Abstract][Full Text] [Related]
28. Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of Tuberculosis.
Orr MT; Windish HP; Beebe EA; Argilla D; Huang PW; Reese VA; Reed SG; Coler RN
J Infect Dis; 2015 Aug; 212(3):495-504. PubMed ID: 25637347
[TBL] [Abstract][Full Text] [Related]
29. Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach.
Kramer RM; Archer MC; Orr MT; Dubois Cauwelaert N; Beebe EA; Huang PD; Dowling QM; Schwartz AM; Fedor DM; Vedvick TS; Fox CB
Int J Nanomedicine; 2018; 13():3689-3711. PubMed ID: 29983563
[TBL] [Abstract][Full Text] [Related]
30. High mobility group box 1 acts as an adjuvant for tuberculosis subunit vaccines.
Grover A; Troudt J; Foster C; Basaraba R; Izzo A
Immunology; 2014 May; 142(1):111-23. PubMed ID: 24350616
[TBL] [Abstract][Full Text] [Related]
31. Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model.
Billeskov R; Christensen JP; Aagaard C; Andersen P; Dietrich J
PLoS One; 2013; 8(8):e72185. PubMed ID: 23977248
[TBL] [Abstract][Full Text] [Related]
32. Differential Immunogenicity and Protective Efficacy Elicited by MTO- and DMT-Adjuvanted CMFO Subunit Vaccines against
Ullah N; Hao L; Wu Y; Zhang Y; Lei Q; Banga Ndzouboukou JL; Lin X; Fan X
J Immunol Res; 2020; 2020():2083793. PubMed ID: 32953889
[TBL] [Abstract][Full Text] [Related]
33. Incorporation of immunostimulatory motifs in the transcribed region of a plasmid DNA vaccine enhances Th1 immune responses and therapeutic effect against Mycobacterium tuberculosis in mice.
Wu J; Ma H; Qu Q; Zhou WJ; Luo YP; Thangaraj H; Lowrie DB; Fan XY
Vaccine; 2011 Oct; 29(44):7624-30. PubMed ID: 21856352
[TBL] [Abstract][Full Text] [Related]
34. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
Front Immunol; 2020; 11():575504. PubMed ID: 33117374
[TBL] [Abstract][Full Text] [Related]
35. Potentiation of Th1-Type Immune Responses to
Ko A; Wui SR; Ryu JI; Lee YJ; Hien DTT; Rhee I; Shin SJ; Park SA; Kim KS; Cho YJ; Lee NG
J Microbiol Biotechnol; 2018 Jan; 28(1):136-144. PubMed ID: 29081214
[TBL] [Abstract][Full Text] [Related]
36. Cell wall skeleton of Mycobacterium bovis BCG enhances the vaccine potential of antigen 85B against tuberculosis by inducing Th1 and Th17 responses.
Back YW; Choi S; Choi HG; Shin KW; Son YJ; Paik TH; Kim HJ
PLoS One; 2019; 14(3):e0213536. PubMed ID: 30849108
[TBL] [Abstract][Full Text] [Related]
37. The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4⁺ T-cells that protect against pulmonary infection in HLA-DR transgenic mice and guinea pigs.
Commandeur S; van den Eeden SJ; Dijkman K; Clark SO; van Meijgaarden KE; Wilson L; Franken KL; Williams A; Christensen D; Ottenhoff TH; Geluk A
Vaccine; 2014 Jun; 32(29):3580-8. PubMed ID: 24837764
[TBL] [Abstract][Full Text] [Related]
38. TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines.
Tyne AS; Chan JG; Shanahan ER; Atmosukarto I; Chan HK; Britton WJ; West NP
Vaccine; 2013 Sep; 31(40):4322-9. PubMed ID: 23880366
[TBL] [Abstract][Full Text] [Related]
39. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and Protective Efficacy of a Fusion Protein Tuberculosis Vaccine Combining Five Esx Family Proteins.
Xiang ZH; Sun RF; Lin C; Chen FZ; Mai JT; Liu YX; Xu ZY; Zhang L; Liu J
Front Cell Infect Microbiol; 2017; 7():226. PubMed ID: 28620588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
